I have previously reported that I was recently denied renewal of my script for the Libre 3 CGM because the FDA had not approved it yet. When I brought this up at my dialysis team meeting last week, my nephrologist, Dr. Turner, questioned why, and I was at a loss to answer.
Since then, I have extensively researched this situation and, quite frankly, have NOT found any definitive research into it. At best, there is anecdotal suggestion that in PD patients, the PD fluid, which contains glucose, may be interfering or reacting with the resident glucose attempted to be measured by the CGM, resulting in an erroneous reading, typically hypoglycemic. Again, as previously reported, I experienced an excessive amount of low glucose alarms with the Libre 3 as many as six nights in a row rendering the use of the CGM moot.
While browsing FB recently, I encountered an ad for a CGM system named Eversense365 CGM. This device is embedded under your upper arm by your GP in office, is touted to last for a year, and is covered by Medicare. What all the PR BS fails to mention is if it works with and on PD patients. They are to call me shortly and I’ll report what transcribes.
Leave a Reply